Latest From Oxurion NV
The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Pipeline Watch: Phase III Progress With Roche's Baloxavir, Pfizer's Tanezumab And Takeda's Vedolizumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With Jetrea being a disappointment on the commercial front, the Belgian biotech will hope that a new name will augur well for its pipeline of disease modifying compounds for diabetic eye disease.
- Large Molecule
- Therapeutic Areas
- ThromboGenics NV
- Western Europe
- Parent & Subsidiaries
- Oxurion NV
- Senior Management
Patrick De Haes, MD, CEO
Dominique Vanfleteren, CFO
Stuart Laermer, CBO
Susan Schneider, MD, ThromboGenics NV
Vinciane Vangeersdaele, Chief Commercial Officer
- Contact Info
Phone: (32) 16 75 1310
Gaston Geenslaan 1
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.